Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination [PDF]
Vaccines, 2023 With concerns about the efficacy of repeat annual influenza vaccination, it is important to better understand the impact of priming vaccine immunity and develop an effective vaccination strategy. Here, we determined the impact of heterologous prime-boost
Noopur Bhatnagar +8 more
doaj +5 more sources
Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression [PDF]
Cell Reports, 2023 Summary: Therapeutic neoantigen cancer vaccines have limited clinical efficacy to date. Here, we identify a heterologous prime-boost vaccination strategy using a self-assembling peptide nanoparticle TLR-7/8 agonist (SNP) vaccine prime and a chimp ...
Ramiro A. Ramirez-Valdez +13 more
doaj +6 more sources
Human Vaccines & Immunotherapeutics, 2022 Mass vaccination with a safe and effective vaccine may be the best way to control the COVID-19 pandemic. Heterologous prime-boost vaccination with the CoronaVac and AZD1222 vaccines may increase the immunogenicity elicited by either vaccine alone.
Guy Cohen +11 more
doaj +3 more sources
Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants [PDF]
Frontiers in ImmunologyHeterologous vaccination strategies have shown superior efficacy over homologous regimens in clinical studies, but the underlying immunological mechanisms remain incompletely understood.
Ji Hyang Jeon +13 more
doaj +3 more sources
Revival of the heterologous prime‐boost technique in COVID‐19: An outlook from the history of outbreaks [PDF]
Health Science Reports, 2022 Background The heterologous prime‐boost vaccination technique is not novel as it has a history of deployment in previous outbreaks. Aim Hence, this narrative review aims to provide critical insight for reviving the heterologous prime‐boost immunization ...
Amna Siddiqui +5 more
doaj +3 more sources
Heterologous prime-boost H1N1 vaccination exacerbates disease following challenge with a mismatched H1N2 influenza virus in the swine model [PDF]
Frontiers in Immunology, 2023 Influenza A viruses (IAVs) pose a significant threat to both human and animal health. Developing IAV vaccine strategies able to elicit broad heterologous protection against antigenically diverse IAV strains is pivotal in effectively controlling the ...
Vasilis C. Pliasas +17 more
doaj +2 more sources
Heterologous Prime–Boost Vaccination with GRA35-Encoding DNA and mRNA Vaccines Enhances Protective Immunity Against Toxoplasma gondii Infection in Mouse Models [PDF]
MicroorganismsToxoplasma gondii is an obligate intracellular protozoan parasite that causes toxoplasmosis, posing a significant threat to human health and livestock production worldwide.
Sisi Chen +4 more
doaj +2 more sources
Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial [PDF]
Frontiers in Immunology, 2023 Background/PurposeOptimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination.
Leyla Sharifi Aliabadi +8 more
doaj +2 more sources
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study [PDF]
Human Vaccines & Immunotherapeutics, 2023 The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses,
Kriangkrai Tawinprai +9 more
doaj +2 more sources
Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses
Molecular Therapy: Oncolytics, 2020 Cancer vaccination aims at inducing an adaptive immune response against tumor-derived antigens. In this study, we utilize recombinant human adenovirus serotype 5 (rAd5) and recombinant lymphocytic choriomeningitis virus (rLCMV)-based vectors expressing ...
Sandra S. Ring +7 more
doaj +3 more sources